Literature DB >> 18493921

Chemotherapy in the treatment of locally advanced head and neck cancer.

Arlene A Forastiere1.   

Abstract

Three decades of collaborative research have led to the integration of platinum-based chemotherapy into the curative management of squamous cell carcinoma of the head and neck and gains in local-regional control, organ preservation and survival endpoints. Concomitant cisplatin-based chemotherapy and radiotherapy is the strategy that has proven most effective for organ preservation for larynx and oropharynx cancers, the treatment of unresectable disease, nasopharyngeal cancer and the post-operative adjuvant treatment of patients at high risk of recurrence. The evolution of current indications for this multimodality approach is reviewed and current areas of investigation discussed. Nearly all patients with locally advanced head and neck cancer receive chemotherapy as part of initial curative treatment. The focus of future trials should be on survival improvement, toxicity reduction and risk stratification for treatment decision making. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493921     DOI: 10.1002/jso.21012

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  34 in total

Review 1.  Head and neck cancer stem cells.

Authors:  S Krishnamurthy; J E Nör
Journal:  J Dent Res       Date:  2011-09-20       Impact factor: 6.116

Review 2.  Current concepts of organ preservation in head and neck cancer.

Authors:  C-J Wang; R Knecht
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-11-25       Impact factor: 2.503

3.  Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.

Authors:  Michael W Sim; Patrick T Grogan; Chitra Subramanian; Carol R Bradford; Thomas E Carey; M Laird Forrest; Mark E Prince; Mark S Cohen
Journal:  Laryngoscope       Date:  2015-12-21       Impact factor: 3.325

4.  Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells.

Authors:  Sudha Krishnamurthy; Zhihong Dong; Dmitry Vodopyanov; Atsushi Imai; Joseph I Helman; Mark E Prince; Max S Wicha; Jacques E Nör
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

5.  Optimising Radiation Therapy Dose to the Swallowing Organs at Risk: An In Silico Study of feasibility for Patients with Oropharyngeal Tumours.

Authors:  Molly K Barnhart; Bena Cartmill; Elizabeth C Ward; Elizabeth Brown; Jonathon Sim; George Saade; Sandra Rayner; Rachelle A Robinson; Virginia A Simms; Robert I Smee
Journal:  Dysphagia       Date:  2019-02-11       Impact factor: 3.438

6.  Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-25       Impact factor: 2.503

7.  Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status.

Authors:  Vlad C Sandulache; Heath D Skinner; Thomas J Ow; Aijun Zhang; Xuefeng Xia; James M Luchak; Lee-Jun C Wong; Curtis R Pickering; Ge Zhou; Jeffrey N Myers
Journal:  Cancer       Date:  2011-06-30       Impact factor: 6.860

Review 8.  HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection.

Authors:  Mary Roz Timbang; Michael W Sim; Arnaud F Bewley; D Gregory Farwell; Avinash Mantravadi; Michael G Moore
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

Review 9.  Current trends in initial management of oropharyngeal cancer: the declining use of open surgery.

Authors:  Missak Haigentz; Carl E Silver; June Corry; Eric M Genden; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12       Impact factor: 2.503

10.  Prognostic and therapeutic potential of nuclear receptors in head and neck squamous cell carcinomas.

Authors:  Shirley K Knauer
Journal:  J Oncol       Date:  2009-09-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.